Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10312765" target="_blank" >RIV/00216208:11110/15:10312765 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61988987:17110/15:A1601FXG RIV/00843989:_____/15:E0104883 RIV/00064165:_____/15:10312765

Výsledek na webu

<a href="http://dx.doi.org/10.1111/bjh.13582" target="_blank" >http://dx.doi.org/10.1111/bjh.13582</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/bjh.13582" target="_blank" >10.1111/bjh.13582</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up

Popis výsledku v původním jazyce

This follow-up extension of a randomised phase II study assessed differences in long-term outcomes between bortezomib-thalidomide-dexamethasone (VTD) and VTD-cyclophosphamide (VTDC) induction therapy in multiple myeloma. Newly diagnosed patients (n = 98)were randomised 1: 1 to intravenous bortezomib (1.3 mg/m(2); days 1, 4, 8, 11), thalidomide (100 mg; days 1-21), and dexamethasone (40 mg; days 1-4, 9-12), with/without cyclophosphamide (400 mg/m(2); days 1, 8), for four 21-day cycles before stem-cell mobilisation/transplantation. After a median follow-up of 64.8 months, median time-to-next therapy was 51.8 and 47.9 months with VTD and VTDC, respectively. Type of subsequent therapy was similar in both arms. After adjusting for asymmetric censoring, median time to progression was not significantly different between VTD and VTDC [35.7 vs. 34.5 months; Hazard ratio (HR) 1.26, 95% confidence interval: 0.76-2.09; P = 0.370]. Five-year survival was 69.1% and 65.3% with VTD and VTDC, respecti

Název v anglickém jazyce

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up

Popis výsledku anglicky

This follow-up extension of a randomised phase II study assessed differences in long-term outcomes between bortezomib-thalidomide-dexamethasone (VTD) and VTD-cyclophosphamide (VTDC) induction therapy in multiple myeloma. Newly diagnosed patients (n = 98)were randomised 1: 1 to intravenous bortezomib (1.3 mg/m(2); days 1, 4, 8, 11), thalidomide (100 mg; days 1-21), and dexamethasone (40 mg; days 1-4, 9-12), with/without cyclophosphamide (400 mg/m(2); days 1, 8), for four 21-day cycles before stem-cell mobilisation/transplantation. After a median follow-up of 64.8 months, median time-to-next therapy was 51.8 and 47.9 months with VTD and VTDC, respectively. Type of subsequent therapy was similar in both arms. After adjusting for asymmetric censoring, median time to progression was not significantly different between VTD and VTDC [35.7 vs. 34.5 months; Hazard ratio (HR) 1.26, 95% confidence interval: 0.76-2.09; P = 0.370]. Five-year survival was 69.1% and 65.3% with VTD and VTDC, respecti

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

British Journal of Haematology

ISSN

0007-1048

e-ISSN

—

Svazek periodika

171

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

11

Strana od-do

344-354

Kód UT WoS článku

000363946100007

EID výsledku v databázi Scopus

2-s2.0-84944274779